Why Roivant Sciences Stock Is Soaring Today
Werte in diesem Artikel
Shares of Roivant Sciences (NASDAQ: ROIV) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday. The big gain came after Roivant and Priovant Therapeutics announced positive results from a late-stage clinical study evaluating brepocitinib in treating dermatomyositis, an autoimmune disease that can cause muscle weakness and skin lesions. Patients receiving a once-daily 30 mg dose of oral brepocitinib experienced statistically significant improvement compared to placebo on the primary endpoint of the phase 3 clinical study as well as all nine key secondary endpoints. Brepocitinib's safety profile was also encouraging, with adverse events of special interest such as malignancy, cardiovascular events, and thromboembolic events not occurring at a greater frequency than with patients in the placebo arm of the study.Priovant Therapeutics now plans to file for U.S. Food and Drug Administration (FDA) approval of brepocitinib in treating dermatomyositis in the first half of 2026. That's great news for Roivant for a simple reason: It owns 75% of Priovant. Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf Roivant Sciences
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Roivant Sciences
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
Nachrichten zu Roivant Sciences
Analysen zu Roivant Sciences
Keine Analysen gefunden.